These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?
The Chart of the Day belongs to the biotechnology company Dyne Therapeutics (DYN) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals,...
Insiders sold more than 15,000 shares of company stock on Tuesday.
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 ...
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass.,...
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical...
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial in Patients with Mutations Amenable to Skipping Exon 51 On Track for Mid-2022 - WALTHAM,...
WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative...
- Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 - ...
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 - WALTHAM,...